US Edition
News from cancernetwork.com
Top cancernetwork.com News
European Union · WaterlooCabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine...See the Story
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
88% Left coverage: 8 sources
NHS · Belgium/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company,...See the Story
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
100% Center coverage: 3 sources
FDA · United StatesThe FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license application for vusolimogene oderparepvec in combination with nivolumab for the treatment of advanced melanoma.According to a company press release, the letter indicates that the FDA cannot approve the application for vusolimogene oderparepvec (RP1) — the company’s leadSee the Story
FDA Rejects RP1 for Advanced Melanoma, Says IGNYTE Not a ‘Well-Controlled’ Trial
67% Center coverage: 3 sources
